HHZ Respiratory Review

CPAP Price in India (2026): Brackets, Drivers, and Channel Tracker

CPAP pricing in India in 2026 spans a roughly 10x range — from sub-₹18,000 entry-tier APAPs to ₹1.8 lakh travel-APAP kits — reflecting a market where several distinct value propositions coexist. Understanding what you are actually paying for at each bracket matters, because the spec differences that explain a 3x price gap are not always what the brochure emphasizes. This guide breaks down the 2026 Indian CPAP market by price bracket, explains what drives the gap, and walks through channel pricing reality, GST, customs, and typical dealer markup.

Price-sampling caveat up front. The prices quoted here are current Indian e-commerce and dealer-channel listings as observed at the time of writing. CPAP prices in the Indian market move seasonally, promotionally, and with currency fluctuation on imported devices. Verify the current price with the specific dealer at time of purchase. Prices also vary between online and offline channels, between direct-dealer purchase and clinic-channel purchase, and between metros and tier-2+ cities. This is a guide to the shape of the market, not a firm quote.

Price brackets in the Indian CPAP market, 2026

Entry-tier (fixed-pressure and basic APAP): ₹17,000–₹30,000

This bracket includes the price floor of the Indian market — devices that can deliver therapy at a pressure somewhere in the 4–20 cmH₂O window, with heated humidification, SD-card data, and 2-year warranties. Algorithms are standard-tier. Data platforms are compliance-reporting only, not live cloud. Build is typically heavier (2–2.5 kg) and noise is at the upper end (28–30 dB).

Representative devices:

The Oxymed at the top of this bracket is disproportionately better-value than the BMC at the bottom because of the 3-year home-service warranty. The ~₹11,000 delta buys an extra year of warranty plus a service-delivery model that materially changes the ownership experience.

Mid-tier APAP: ₹30,000–₹50,000

This bracket is where the Indian market concentrates — mid-tier APAPs with functional algorithms, cleaner build, and reasonable data. Most Indian patients who can afford ResMed or Philips premium devices end up here on a price-versus-features tradeoff.

Representative devices:

Premium APAP: ₹50,000–₹85,000

This bracket is where the flagship algorithms and platforms live. The cost delta from mid-tier is primarily about algorithm sophistication (AutoSet vs standard-tier), data ecosystem (AirView live cloud vs SD-card compliance), build quality, and heated-humidification integration.

Representative devices:

Travel-CPAP premium: ₹75,000–₹1.8L (kits)

Dedicated travel CPAPs are engineered to deliver full-therapy algorithm quality at 300–400 g. The cost-per-gram of engineering is substantial.

Representative:

Third-party kit bundles with batteries, carrying cases, and mask selection bring total outlay into the ₹1.2L–₹1.8L territory for the premium travel setup. For most Indian CPAP users travel-device ownership is only justified if they travel more than 4–6 weeks a year or have a specific travel requirement (overseas deployment, frequent international conference travel) where carrying a home unit is impractical.

What drives the price gap

Four factors explain the 10x range in the Indian CPAP market.

1. Algorithm sophistication

This is the single largest driver of the premium tier’s cost. The difference between a ResMed AutoSet algorithm and a standard-tier APAP algorithm is not marketing; it is measurable in residual AHI, adherence, and patient comfort on controlled comparisons. AutoSet and similar advanced algorithms are the result of decades of R&D and clinical validation — the R&D amortization is embedded in the device price.

Practical consequence: a ₹18,000 BMC RESmart GII will auto-titrate and suppress most events, but it does not reliably discriminate central apneas from obstructive events, does not tune the response curve based on flow-limitation morphology, and does not deploy a gender-specific algorithm. For uncomplicated mild OSA that is often fine. For moderate-to-severe OSA with comorbidity, the algorithm delta matters clinically.

2. Integrated heated humidification

The humidifier quality delta across the Indian market is larger than most patients realize. ResMed’s HumidAir + ClimateLineAir is an integrated system that measures ambient conditions and automatically adjusts humidity and heated-tube temperature to maintain a target absolute humidity at the mask. Philips DreamStation humidifiers do similar. The lower-tier heated humidifiers are passive — set at a humidity level, run at that level, no active adjustment.

In humid Mumbai or Kolkata summers, a passive humidifier set at level 4 produces condensate rainout in the tube; in dry Delhi winter a passive humidifier set at level 4 is insufficient to prevent airway dryness. The ResMed-style integrated humidifier handles both conditions without user intervention. This matters every night for 5–10 years.

3. Data platform — live cloud vs SD-card compliance

ResMed AirView, Philips Care Orchestrator, and (per manufacturer) Oxymed’s cloud platform push compliance data, residual-event data, and leak data to the prescribing physician without patient involvement. SD-card-only devices require the patient to bring the device in for data extraction — which most patients don’t do.

The cost to the OEM of the cellular or Bluetooth-connected data platform is real (modem hardware, cellular service fees, platform maintenance, clinician platform access). It is baked into the premium-tier price. For patients whose physician actively manages them remotely, it is worth the cost. For patients whose physician never looks at the data, it is not.

4. Mask-fit guidance, advanced event detection, ancillary features

Features like ResMed’s Mask Fit verification routine, auto-ramp with sleep-onset detection, Central Apnea Detection with algorithm-correct response (hold pressure, don’t chase), climate control, preheat, and advanced leak-detection add incrementally to the value proposition. Each feature is a small R&D investment and a small price contribution. Cumulatively they explain part of the price premium.

Channel pricing reality

CPAP pricing in India varies meaningfully by channel.

E-commerce (dedicated respiratory channels, general e-commerce): typically the lowest prices. Channel discounting of 30–45% off MRP is routine for imported premium devices (ResMed, Philips, Wellel); Indian-manufactured devices discount 15–30% off MRP. Prices quoted in this guide are approximate channel-observed figures.

Authorized dealer direct purchase: typically 5–15% higher than online. The dealer provides in-person setup, mask fitting, and prescription-pressure loading, which has value for first-time buyers. Many dealers price-match online prices on request but not by default.

Hospital clinic channel: typically 10–25% higher than online. Devices sold through hospital respiratory-medicine departments or sleep clinics often carry markup. The argument for clinic-channel purchase is bundled care — follow-up review, titration adjustment, compliance review — but the price delta is substantial.

Medical device pharmacies and general medical equipment stores: pricing varies. Some price competitively, some price above authorized dealer MRP. Authenticity of the unit is occasionally a concern; verify OEM serial number before purchase.

Classified marketplaces and used-device listings: prices 30–60% below new. Warranty is usually voided on transfer; service-network access is dealer-dependent. Risk category for anything beyond an experienced buyer.

GST and customs

CPAP devices in the current GST schedule are taxed at 12% (medical devices, HSN code 9019). The quoted current prices are inclusive of GST in most e-commerce listings; confirm GST inclusion on the specific invoice.

Customs duty on imported CPAP devices is embedded in the MRP by the importer (ResMed India, Philips Healthcare India, etc.). Buyers do not pay customs separately; the importer has already absorbed and amortized it into the pricing structure. The effective customs-plus-GST overhead on an imported premium CPAP is substantial — roughly 25–35% of the CIF price — which is why the MRP of a ResMed AirSense 11 in India (₹1,05,600) is meaningfully above the US retail price converted at FX (~$920–$1,050 US retail = ₹77,000–₹87,000 at current FX). The Indian channel discount partially offsets this, but the baseline Indian price is a ~15–20% premium to converted-FX US pricing even after discounting.

Indian-manufactured devices (BPL, Deckmount) do not carry the customs loading but do carry the cost of Indian component sourcing and assembly, which partially offsets. Indian-assembled devices using imported turbines (Oxymed’s “German turbine” per manufacturer brochure, Wellel’s Taiwanese turbine) sit in between on cost structure.

Typical dealer markup

Indian CPAP dealer margins in 2026 are approximately:

These figures are approximate and vary by dealer, region, and volume. A high-volume metro dealer can run at lower margin and compensate on volume; a tier-2 city dealer often carries higher margin to offset lower throughput.

Mask and consumable margins are typically higher than device margins — 30–50% on original-brand masks, 40–60% on humidifier chambers, 40–60% on tubing. Dealers who discount the device aggressively often recover margin on consumables. The lifetime consumables bill on a CPAP over 5 years (₹25,000–₹50,000 including mask replacements, humidifier chambers, tubing, filters) is a meaningful component of dealer economics and should be a factor in choosing a dealer — a dealer who overcharges on consumables relative to online is extracting over the lifetime of the device.

Where the 2026 Indian market is moving

Three trends visible in late 2025/early 2026 pricing:

  1. AirSense 11 channel price is compressing: the flagship has moved from a launch channel price near ₹80,000 to current ~₹63,000, reflecting maturity and competitive pressure from the AirSense 10 (still in channel) and from lower-tier APAPs offering functional therapy.

  2. TVAPS and volume-targeted bilevel prices are becoming accessible: the BMC G3 B30VT at ₹39,744 and the Oxymed AirSmart BPAP ST with VAPS at ₹37,490 bring volume-assured bilevel therapy into the sub-₹40,000 bracket — which ResMed and Philips equivalents (Lumis 150 VPAP ST Tripack at ₹63,490, DreamStation BiPAP AVAPS at ₹77,952) do not match. This is a structural shift; see our TVAPS guide for the clinical implications.

  3. Oxymed’s 3-year PAN-India warranty model is pressuring the market: 2-year imported-device warranties are starting to look thin against a 3-year domestic warranty with home service. Expect ResMed and Philips India to extend warranty terms or bundle service contracts in response.

Sampling disclaimer and how prices were observed

The prices quoted throughout this guide are based on Indian e-commerce and dealer-channel listings as observed at the time of writing, drawn from manufacturer brochures and e-commerce product listings. The methodology for the price-sampling:

CPAP prices in India move seasonally (Diwali, FY-end campaigns), with currency fluctuation (USD/INR and EUR/INR affect imported devices), and with competitive response (ResMed’s AirSense 11 channel discount deepens when Philips promotes the DreamStation). Treat the figures here as shape-of-market guidance; for firm pricing get a current written quote from the specific dealer you plan to buy from.

Total cost of ownership over 5 years

Device price is only one component of the total CPAP ownership bill. A realistic 5-year TCO calculation for a ₹28,499 mid-tier APAP in India:

For a ₹63,390 flagship APAP (ResMed AirSense 11):

The device-price delta between mid-tier and flagship (₹34,891) compounds to a TCO delta of ~₹65,000 over 5 years, largely through consumables cost differentials. This is worth understanding when comparing bracket-to-bracket. Patients who buy flagship can also choose third-party masks, filters, and tubing to bring consumables cost down toward mid-tier levels — at some cost in brand-optimized mask-fit, filtration quality, and heated-tube climate control.

EMI and financing in the Indian CPAP market

CPAP purchases on EMI are increasingly common in the Indian market, offered through:

For most Indian buyers, 6-month no-cost-EMI through dealer or credit card is the cheapest financing path. 9- and 12-month EMIs at small-APR from dealer partners work for cash-flow management.

Used, refurbished, and import-duty-paid vs grey-channel pricing

A price tier below new-retail exists on used/refurbished devices:

The used/refurbished market in India is likely to grow as the 2018–2020 cohort of new ResMed and Philips devices reaches 5–7 year age and is cycled out by upgrading owners. Expect dealer-refurbished inventory to become a meaningful segment by 2027–2028.

Final guide to the price bracket decision

Work backwards from clinical requirement and budget:

For deeper exploration of each category see the APAP guide, Fixed-pressure CPAP guide, and brand landscape.